Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Nov;10(11):e1655-e1664.
doi: 10.1016/S2214-109X(22)00379-5.

Evaluating the effect of measles and rubella mass vaccination campaigns on seroprevalence in India: a before-and-after cross-sectional household serosurvey in four districts, 2018-2020

Affiliations

Evaluating the effect of measles and rubella mass vaccination campaigns on seroprevalence in India: a before-and-after cross-sectional household serosurvey in four districts, 2018-2020

Manoj V Murhekar et al. Lancet Glob Health. 2022 Nov.

Abstract

Background: India did phased measles-rubella supplementary immunisation activities (MR-SIAs; ie, mass-immunisation campaigns) targeting children aged 9 months to less than 15 years. We estimated measles-rubella seroprevalence before and after the MR-SIAs to quantify the effect on population immunity and identify remaining immunity gaps.

Methods: Between March 9, 2018 and March 19, 2020 we did community-based, cross-sectional serosurveys in four districts in India before and after MR-SIAs. 30 villages or wards were selected within each district, and one census enumeration block from each was selected as the survey cluster. Households were enumerated and 13 children in the younger age group (9 months to <5 years) and 13 children in the older ager group (5 to <15 years) were randomly selected by use of computer-generated random numbers. Serum samples were tested for IgG antibodies to measles and rubella viruses by enzyme immunoassay.

Findings: Specimens were collected from 2570 children before the MR-SIA and from 2619 children afterwards. The weighted MR-SIA coverage ranged from 73·7% to 90·5% in younger children and from 73·6% to 93·6% in older children. Before the MR-SIA, district-level measles seroprevalence was between 80·7% and 88·5% among younger children in all districts, and between 63·4% and 84·5% among older children. After the MR-SIA, measles seroprevalence among younger children increased to more than 90% (range 91·5 to 96·0) in all districts except Kanpur Nagar, in which it remained unchanged 80·4%. Among older children, measles seroprevalence increased to more than 90·0% (range 93·7% to 96·5%) in all districts except Hoshiarpur (88·7%). A significant increase in rubella seroprevalence was observed in all districts in both age groups, with the largest effect in Dibrugarh, where rubella seroprevalence increased from 10·6% to 96·5% among younger children.

Interpretation: Measles-rubella seroprevalence increased substantially after the MR-SIAs but the serosurvey also identified remaining gaps in population immunity.

Funding: The Bill & Melinda Gates Foundation and Indian Council of Medical Research.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests KH has been an employee by Pfizer Vaccines from October 26, 2020. All other authors declare no competing interests.

Figures

Figure 1
Figure 1
Study profile *Enumeration involved visiting all households in the cluster to collect identification details (name, date of birth or age, and gender). †Children available for the next 3 days. ‡Automated random selection of children from enumeration data using an in-house app developed for the purpose. §Children with adequate sample volume were tested and analysed in the final dataset.
Figure 2
Figure 2
Seroprevalence of IgG antibodies against measles and rubella viruses before and after the MR-SIA, by district Bars represent the weighted seroprevalence estimates for the pre-MR-SIA serosurvey and the post-MR-SIA serosurvey. Lines at the top of each bar represent 95% CIs. Age-specific weighted seroprevalence of IgG antibodies against measles and rubella viruses were estimated with Wald 95% CIs (black bars) using a random-intercept logistic regression model that included sampling weights based on survey design. Equivocal results were classified as seropositive. SIA=supplementary immunisation activities.
Figure 3
Figure 3
Age-specific measles and rubella seroprevalence among serosurvey participants, by district Weighted age-specific seroprevalence for measles (A) and rubella IgG (B), before and after the measles and rubella supplementary immunisation activities campaign. Shaded areas denote 95% CIs. Equivocal results were classified as positive. Coloured dots denote seroprevalence point estimates for each age by year, estimated using used semiparametric models with penalised regression smoothers, with dot size based on the number of participants who had available data. Age reflects participant age at time of the survey; owing to the time difference between the MR-SIA and the surveys, there were children enrolled in the post-MR-SIA surveys who were older than 15 years at time of the survey, including a small number aged 16 years or older in Dibrugarh and Hoshiarpur districts.

References

    1. Dixon MG, Ferrari M, Antoni S, et al. Progress toward regional measles elimination—worldwide, 2000–2020. MMWR Morb Mortal Wkly Rep. 2021;70:1563–1569. - PMC - PubMed
    1. Vynnycky E, Adams EJ, Cutts FT, et al. Using seroprevalence and immunisation coverage data to estimate the global burden of congenital rubella syndrome, 1996–2010: a systematic review. PLoS One. 2016;11 - PMC - PubMed
    1. Ministry of Health and Family Welfare. Government of India National Family Health Survey-1, 1992–93. India main report. August, 1995. http://rchiips.org/NFHS/data/india1/iachap9.pdf
    1. Government of India Ministry of Health and Family Welfare National Family Health Survey—5. 2019–21. India factsheet. November, 2021. http://rchiips.org/nfhs/NFHS-5_FCTS/India.pdf
    1. Gupta SK, Sosler S, Haldar P, Hombergh H, Bose AS. Introduction strategy of a second dose measles containing vaccine in India. Indian Pediatr. 2011;48:379–382. - PubMed

Publication types

Substances